BioSpace News Archive

Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the presentation of an interim analysis of the Phase 1 portion of a first-in-human Phase 1/2 study of CYT-0851

The report highlights the trends prevalent in the coronary stents market and the factors driving the market along with those that act as deterrents to its growth.

Enzymes play a crucial role in the metabolic activities of all organisms, whether animal, human, plant, or microbial.

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Kite, a Gilead Company (Nasdaq: GILD), announced today results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/2 study evaluating its chimeric antigen receptor (CAR) T-cell therapy Tecartus

The data are being presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually.

- Despite being recognized by leading authorities as a serious disease, obesity remains stigmatized, resulting in patients being underdiagnosed and significantly undertreated - Approval includes results from STEP 1, a clinical trial where once-weekly, prescription GLP-1 receptor agonist Wegovy™ (semaglutide) injection 2.4 mg, demonstrated an average weight loss of ~15% at 68-weeks when used with a reduced calorie meal plan and increased physical activity

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 44,200 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

LUMAKRAS Shows Median Overall Survival of 12.5 Months in Patients With Previously Treated Non-Small Cell Lung Cancer Data Confirms Rapid, Deep, and Durable Responses With Median Duration of Response of 11.1 Months Data Presented at ASCO 2021 and Simultaneously Published in New England Journal of Medicine

Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial.